Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.40
CELG's Cash to Debt is ranked lower than
89% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. CELG: 0.40 )
Ranked among companies with meaningful Cash to Debt only.
CELG' s Cash to Debt Range Over the Past 10 Years
Min: 0.27  Med: 1.88 Max: No Debt
Current: 0.4
Equity to Asset 0.20
CELG's Equity to Asset is ranked lower than
88% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CELG: 0.20 )
Ranked among companies with meaningful Equity to Asset only.
CELG' s Equity to Asset Range Over the Past 10 Years
Min: -0.68  Med: 0.59 Max: 0.92
Current: 0.2
-0.68
0.92
Interest Coverage 6.25
CELG's Interest Coverage is ranked lower than
84% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 6.25 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s Interest Coverage Range Over the Past 10 Years
Min: 7.26  Med: 27.63 Max: 428.04
Current: 6.25
7.26
428.04
F-Score: 5
Z-Score: 3.86
M-Score: -2.33
WACC vs ROIC
12.32%
18.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 24.75
CELG's Operating margin (%) is ranked higher than
89% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. CELG: 24.75 )
Ranked among companies with meaningful Operating margin (%) only.
CELG' s Operating margin (%) Range Over the Past 10 Years
Min: -64.94  Med: 28.83 Max: 32.84
Current: 24.75
-64.94
32.84
Net-margin (%) 17.38
CELG's Net-margin (%) is ranked higher than
87% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. CELG: 17.38 )
Ranked among companies with meaningful Net-margin (%) only.
CELG' s Net-margin (%) Range Over the Past 10 Years
Min: -68.02  Med: 23.31 Max: 28.88
Current: 17.38
-68.02
28.88
ROE (%) 28.58
CELG's ROE (%) is ranked higher than
96% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. CELG: 28.58 )
Ranked among companies with meaningful ROE (%) only.
CELG' s ROE (%) Range Over the Past 10 Years
Min: -48.42  Med: 21.32 Max: 33.02
Current: 28.58
-48.42
33.02
ROA (%) 7.28
CELG's ROA (%) is ranked higher than
87% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. CELG: 7.28 )
Ranked among companies with meaningful ROA (%) only.
CELG' s ROA (%) Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 7.28
-38.07
15.8
ROC (Joel Greenblatt) (%) 163.22
CELG's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. CELG: 163.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CELG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -421.4  Med: 163.93 Max: 212.3
Current: 163.22
-421.4
212.3
Revenue Growth (3Y)(%) 21.60
CELG's Revenue Growth (3Y)(%) is ranked higher than
76% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CELG: 21.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CELG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 20.6  Med: 40.60 Max: 240.6
Current: 21.6
20.6
240.6
EBITDA Growth (3Y)(%) 13.10
CELG's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CELG: 13.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CELG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.3  Med: 26.60 Max: 297.9
Current: 13.1
-37.3
297.9
EPS Growth (3Y)(%) 5.50
CELG's EPS Growth (3Y)(%) is ranked higher than
63% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CELG: 5.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CELG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.8  Med: 23.65 Max: 113.8
Current: 5.5
-60.8
113.8
» CELG's 10-Y Financials

Financials (Next Earnings Date: 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CELG Guru Trades in Q3 2015

John Burbank 174,768 sh (New)
Murray Stahl 8,000 sh (+60.00%)
Louis Moore Bacon 80,000 sh (+60.00%)
RS Investment Management 130,238 sh (+22.61%)
Mario Gabelli 29,325 sh (+20.85%)
Mairs and Power 2,086 sh (+17.45%)
Ken Fisher 244,564 sh (+8.99%)
Pioneer Investments 3,637,052 sh (+3.24%)
Ken Heebner Sold Out
Lee Ainslie 2,090 sh (-6.28%)
Joel Greenblatt 6,344 sh (-18.44%)
Paul Tudor Jones 8,020 sh (-61.92%)
Jim Simons 378,633 sh (-62.39%)
» More
Q4 2015

CELG Guru Trades in Q4 2015

Steven Cohen 537,800 sh (New)
Mairs and Power 2,681 sh (+28.52%)
Lee Ainslie 2,380 sh (+13.88%)
Pioneer Investments 3,675,883 sh (+1.07%)
Ken Fisher 245,460 sh (+0.37%)
Murray Stahl 8,000 sh (unchged)
Samuel Isaly 256,000 sh (unchged)
Louis Moore Bacon Sold Out
John Burbank Sold Out
Joel Greenblatt Sold Out
Jim Simons Sold Out
Mario Gabelli 29,270 sh (-0.19%)
RS Investment Management 129,300 sh (-0.72%)
Paul Tudor Jones 6,016 sh (-24.99%)
» More
Q1 2016

CELG Guru Trades in Q1 2016

Ray Dalio 4,100 sh (New)
Julian Robertson 228,840 sh (New)
Joel Greenblatt 68,917 sh (New)
Lee Ainslie 4,900 sh (+105.88%)
Pioneer Investments 3,821,415 sh (+3.96%)
Murray Stahl 8,000 sh (unchged)
Samuel Isaly 256,000 sh (unchged)
Paul Tudor Jones Sold Out
Mairs and Power Sold Out
Steven Cohen Sold Out
Mario Gabelli 27,144 sh (-7.26%)
RS Investment Management 111,048 sh (-14.12%)
Ken Fisher 198,160 sh (-19.27%)
» More
2016

CELG Guru Trades in 2016

Spiros Segalas 5,149,008 sh (+10.16%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:BIIB, NAS:GILD, NAS:AMGN, NAS:REGN, OTCPK:CSLLY, OTCPK:SHPGF, NYSE:BXLT, NAS:ALXN, OTCPK:NONOF, NAS:VRTX, OTCPK:ALIOY, NAS:INCY, NAS:BMRN, OTCPK:GIKLY, OTCPK:NVZMY, OTCPK:UCBJY, NAS:MDVN, OTCPK:GMXAY, NAS:JAZZ, NAS:ALKS » details
Traded in other countries:CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Celgene Corp is incorporated in Delaware in 1986. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST, IMNOVID, THALOMID (inclusive of Thalidomide Celgene, ISTODAX and azacitidine for injection (generic version of VIDAZA). It owns and operates a manufacturing facility in Zofingen, Switzerland which produces the active pharmaceutical ingredient (API) for REVLIMID and THALOMID and have contracted with third-party contract manufacturers to provide backup API manufacturing services for these products. Manufacturing services for REVLIMID and THALOMID, which consist of formulation, encapsulation, packaging, warehousing and distribution, are performed at our drug product manufacturing facility in Boudry, Switzerland. The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.

Ratios

vs
industry
vs
history
P/E(ttm) 52.13
CELG's P/E(ttm) is ranked lower than
66% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.09 vs. CELG: 52.13 )
Ranked among companies with meaningful P/E(ttm) only.
CELG' s P/E(ttm) Range Over the Past 10 Years
Min: 17.91  Med: 47.94 Max: 618.72
Current: 52.13
17.91
618.72
Forward P/E 19.01
CELG's Forward P/E is ranked higher than
56% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 21.32 vs. CELG: 19.01 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 52.13
CELG's PE(NRI) is ranked lower than
66% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 29.71 vs. CELG: 52.13 )
Ranked among companies with meaningful PE(NRI) only.
CELG' s PE(NRI) Range Over the Past 10 Years
Min: 17.82  Med: 47.92 Max: 482.6
Current: 52.13
17.82
482.6
Price/Owner Earnings (ttm) 46.92
CELG's Price/Owner Earnings (ttm) is ranked lower than
58% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 34.88 vs. CELG: 46.92 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CELG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 15.44  Med: 44.04 Max: 1163.68
Current: 46.92
15.44
1163.68
P/B 16.48
CELG's P/B is ranked lower than
92% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. CELG: 16.48 )
Ranked among companies with meaningful P/B only.
CELG' s P/B Range Over the Past 10 Years
Min: 4.02  Med: 9.31 Max: 23.65
Current: 16.48
4.02
23.65
P/S 9.06
CELG's P/S is ranked higher than
60% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. CELG: 9.06 )
Ranked among companies with meaningful P/S only.
CELG' s P/S Range Over the Past 10 Years
Min: 5.41  Med: 10.28 Max: 27.13
Current: 9.06
5.41
27.13
PFCF 38.24
CELG's PFCF is ranked lower than
63% of the 147 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. CELG: 38.24 )
Ranked among companies with meaningful PFCF only.
CELG' s PFCF Range Over the Past 10 Years
Min: 14.96  Med: 35.73 Max: 2438.33
Current: 38.24
14.96
2438.33
POCF 33.79
CELG's POCF is ranked lower than
63% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 22.90 vs. CELG: 33.79 )
Ranked among companies with meaningful POCF only.
CELG' s POCF Range Over the Past 10 Years
Min: 13.93  Med: 33.29 Max: 1407
Current: 33.79
13.93
1407
EV-to-EBIT 36.85
CELG's EV-to-EBIT is ranked lower than
69% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. CELG: 36.85 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.6  Med: 35.60 Max: 156.6
Current: 36.85
-28.6
156.6
EV-to-EBITDA 31.34
CELG's EV-to-EBITDA is ranked lower than
69% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. CELG: 31.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.4  Med: 29.40 Max: 132.5
Current: 31.34
-31.4
132.5
PEG 2.69
CELG's PEG is ranked lower than
53% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. CELG: 2.69 )
Ranked among companies with meaningful PEG only.
CELG' s PEG Range Over the Past 10 Years
Min: 1.38  Med: 2.23 Max: 3.24
Current: 2.69
1.38
3.24
Shiller P/E 101.71
CELG's Shiller P/E is ranked lower than
76% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 56.77 vs. CELG: 101.71 )
Ranked among companies with meaningful Shiller P/E only.
CELG' s Shiller P/E Range Over the Past 10 Years
Min: 90.84  Med: 147.21 Max: 3211
Current: 101.71
90.84
3211
Current Ratio 4.57
CELG's Current Ratio is ranked higher than
50% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CELG: 4.57 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 6.43 Max: 44.53
Current: 4.57
1.35
44.53
Quick Ratio 4.32
CELG's Quick Ratio is ranked higher than
51% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. CELG: 4.32 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 6.33 Max: 44.15
Current: 4.32
1.13
44.15
Days Inventory 369.48
CELG's Days Inventory is ranked lower than
89% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. CELG: 369.48 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 66.12  Med: 203.77 Max: 363.39
Current: 369.48
66.12
363.39
Days Sales Outstanding 53.52
CELG's Days Sales Outstanding is ranked higher than
58% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. CELG: 53.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.42  Med: 57.78 Max: 71.28
Current: 53.52
43.42
71.28
Days Payable 190.02
CELG's Days Payable is ranked higher than
82% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. CELG: 190.02 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 109.32 Max: 209.22
Current: 190.02
61.81
209.22

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.54
CELG's Price/Projected FCF is ranked higher than
62% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 3.44 vs. CELG: 2.54 )
Ranked among companies with meaningful Price/Projected FCF only.
CELG' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.66  Med: 5.62 Max: 122.67
Current: 2.54
1.66
122.67
Price/Median PS Value 0.88
CELG's Price/Median PS Value is ranked higher than
58% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CELG: 0.88 )
Ranked among companies with meaningful Price/Median PS Value only.
CELG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.55  Med: 1.36 Max: 30
Current: 0.88
0.55
30
Price/Peter Lynch Fair Value 2.88
CELG's Price/Peter Lynch Fair Value is ranked lower than
71% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.76 vs. CELG: 2.88 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CELG' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.36  Med: 1.42 Max: 5.1
Current: 2.88
0.36
5.1
Earnings Yield (Greenblatt) (%) 2.68
CELG's Earnings Yield (Greenblatt) (%) is ranked higher than
82% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. CELG: 2.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CELG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 2.70 Max: 6.7
Current: 2.68
0.6
6.7
Forward Rate of Return (Yacktman) (%) 20.48
CELG's Forward Rate of Return (Yacktman) (%) is ranked higher than
63% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.20 vs. CELG: 20.48 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CELG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.90 Max: 34.8
Current: 20.48
0.1
34.8

More Statistics

Revenue (TTM) (Mil) $9,687
EPS (TTM) $ 2.07
Beta1.60
Short Percentage of Float1.08%
52-Week Range $92.98 - 136.40
Shares Outstanding (Mil)774.60

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 11,110 13,185 15,597
EPS ($) 5.68 7.03 8.74
EPS w/o NRI ($) 5.68 7.03 8.74
EPS Growth Rate
(3Y to 5Y Estimate)
20.19%
Dividends Per Share ($)
» More Articles for NAS:CELG

Headlines

Articles On GuruFocus.com
Celgene: Is It a Buy? Jun 21 2016 
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
Gilead and Celgene Among Biotechnology Stocks to Buy May 26 2016 
DISH Network, H&R Block, Celgene, Plum Creek Timber Log Largest Insider Sells Jan 04 2016 
Taking a Look at Barron’s 10 Favorite Stocks for 2016 Dec 07 2015 
Celgene: A Primer on Growth Stock Value Investing - Part 2 Nov 13 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
10 Reasons Why Growth Stocks Can Be Appropriate for Retired Investors Jun 04 2015 
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
Celgene’s Earnings Shine While Revenue Misses By An Inch In The First Quarter May 06 2015 

More From Other Websites
Celgene Falls After Blockbuster Cancer Drug Revlimid Fails To Extend Survival Jul 25 2016
Celgene drug fails to extend survival in lymphoma study Jul 25 2016
Celgene Can't Expand Revlimid Approval Into Non-Hodgkin Lymphoma Just Yet Jul 25 2016
What Are Analysts’ Recommendations for Biogen in 2016? Jul 25 2016
Celgene shares slide after Revlimid use expansion curbed Jul 25 2016
Celgene and LYSARC Provide Update on the Phase III ‘REMARC' Study of REVLIMID® Maintenance... Jul 25 2016
4:32 pm Celgene announces the Lymphoma Academic Research Organisation reported initial data from a... Jul 25 2016
Celgene and LYSARC Provide Update on the Phase III ‘REMARC’ Study of REVLIMID® Maintenance... Jul 25 2016
Gilead Sciences: What Do Analysts Recommend? Jul 25 2016
Celgene (CELG) Q2 Earnings: Can the Stock Pull a Surprise? Jul 25 2016
Gilead Sciences Kicks Off 5 Big Pharma Earnings This Week Jul 25 2016
This Week Could Decide Whether Biotech ETFs' Rally Sizzles Or Fizzles Jul 25 2016
Celgene (CELG) Stock Is the ‘Chart of the Day’ Jul 22 2016
Biogen: CEO Departing; Is This Drug Maker In Play? Jul 21 2016
The Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen Jul 21 2016
Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug Jul 20 2016
​Cambridge’s Jounce announces hefty $2.5B deal with Celgene for cancer drugs Jul 20 2016
Biotech: As Cheap as They Come Jul 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)